Information Provided By: 
Fly News Breaks for May 31, 2016
TEVA
May 31, 2016 | 09:48 EDT
Wells Fargo analyst David Maris calls Teva's Complete Response Letter for its chorea-associated Huntington disease treatment SD-809 a "minor negative." The issue or request from the FDA "seems identifiable, addressable, and limited in scope," Maris tells investors in a research note. The analyst now sees approval for SD-809 in 2017. Maris keeps an Outperform rating on Teva with a $68-$71 price target range.
News For TEVA From the Last 2 Days
